To own Exelixis, you need to believe the business can turn Cabometyx into a durable cash engine long enough for zanzalintinib and other oncology assets to matter. The analyst consensus Narrative on Simply Wall St assumes that evolution from a cabozantinib centric model toward a broader portfolio. The recent reminder about potential Cabometyx generics around 2030 does not change the nearer term focus on execution.
Over the next few years, the key swing factor is whether zanzalintinib approvals and launches land roughly as expected while Exelixis keeps R&D around US$1b or less. The biggest current risk is that launch curves or regulatory outcomes for zanzalintinib and newer Cabometyx indications fall short of expectations, leaving the business more exposed as patents age.
The clearest related announcement in the analyst consensus Narrative on Simply Wall St is the three month extension of the PDUFA date for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer. That delay pushes out a potential U.S. launch and keeps investors focused on regulatory risk around what many see as the next franchise pillar.
For you, the read through is practical. In the near term, catalysts skew toward regulatory decisions on zanzalintinib combinations and any updates around CABINET and STELLAR 303 pathways. On the flip side, any further delays, restrictive labels or conservative guidance updates on new indications would reinforce the concern that Cabometyx reliance remains high heading into the 2030 patent window.
Exelixis' current analyst narrative centers on revenues reaching US$3.6b and earnings of US$1.5b by 2029, based on 12.8% yearly top line growth and an earnings increase of about US$615m from US$885.1m today.
Uncover why Exelixis' fair value indicates a 10% potential downside to its current price, which leaves little room for error.
One alternate view focuses less on patent timing and more on Exelixis’ earnings power if zanzalintinib underdelivers. The most cautious analysts were only penciling in about US$3.3b of revenue and US$1.2b of earnings by 2029 before this news. That is far below the US$3.6b and US$1.5b consensus path. Use that spread as a prompt to compare several scenarios and decide which narrative you find more convincing, knowing this latest update could still shift both sets of forecasts.
Explore 3 other Exelixis fair value estimates, including one that suggests a potential 10% downside from the current price.
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider developing your own perspective.
Once you have a view on Exelixis, it can be useful to compare that thesis with other opportunities that share similar qualities, whether you care most about value, resilience, or future potential.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com